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Abstract. It is still necessary to search for new informative diagnostic methods to detect malignant tumors with 
overexpression of Her-2/neu, which are characterized by the aggressive course of the disease, rapid rate of tumor growth 
and low rates of relapse-free and overall survival. In recent years, the radioisotope techniques for detection of specific 
tumor targets have been developing actively. Purpose: to develop a chemically stable radiochemical compound for the 
targeted imaging of cells overexpressing Her-2/neu. Material and methods: The study was performed using 2 cell lines. 
The human breast adenocarcinoma HER2-overexpressing cell line BT-474 was chosen to detect specific binding. As a 
control, HER2-negative human breast adenocarcinoma MCF-7 was used. The human breast adenocarcinoma BT-474 and 
MCF-7 cell lines were seeded in chamber-slides at the density of 35,000 cells/ml in trypsin–EDTA (PanEco) medium and 
grown overnight at 37°C. After that both cell lines were washed with Phosphate buffered saline (PBS) and distributed 
into test tubes to 1 ml (5 millions cells in each). After adding 100 μl (70 MBq) studied complex of 99mTc–DPAH–
DARPinG3 was incubated for 40 min at +4°C. Washing was performed three times with buffer PBS and 5% Bovine 
Serum Albumin (BSA). The characteristics of the binding specificity of the test set with the HER-2/neu receptor were 
determined by direct radiometric and planar scintigraphy. Nonparametric Mann-Whitney test was used to assess the 
differences in the quantitative characteristics between groups. Results: The output of the labeled complex was more than 
91%, with a radiochemical purity of more than 94%. When carrying out a visual scintigraphic assessment much greater 
intensity accumulation of radiotracer was observed in the studied cell culture surface receptor overexpressing Her-2/neu. 
The results of direct radiometric also showed higher accumulation of the radiopharmaceutical in the adenocarcinoma cell 
line BT-474 human breast cancer overexpressing Her-2/neu compared to the control group. Conclusion: The preclinical 
studies demonstrated a high in vitro stability of the study compound, as well as its accumulation in the cell group 
overexpressing Her-2/neu.
Recently, a personified approach has been widely used in the cancer treatment, which consists in the selection of 
a particular category of patients, who would most likely have a response to the treatment according to their 
“molecular profile”. Target therapy is the most demonstrative example of this approach in the treatment of 
oncological patients. Target therapy affects molecular targets which are key to the vital activity of tumor cells with a 
minimal effect on normal tissue cells [1, 2].
Over the past two decades a particular interest has been manifested to the study of surface receptor Her-2/neu, a 
member of transmembrane tyrosine kinase receptors. On the one hand, overexpression of Her-2/neu is a marker of 
unfavourable prognosis of the disease, which is manifested by the aggressive course of the disease, rapid rate of 
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tumor growth and low rates of relapse-free and overall survival. On the other hand, overexpression of Her-2/neu is 
an indication for the target therapy with Herceptin which is still the standard of treatment for patients with Her-
2/neu-positive breast cancer [3, 4].
Currently, there are a number of diagnostic techniques for determination of the Her-2/neu status. The 
immunohistochemical method is often used, although it has a number of drawbacks: the necessity of an invasive 
procedure (taking a biopsy or surgical material), a high incidence of false positive and false negative results, as well 
as a possible violation in methodology and misinterpretation of results [5, 6].
At present, molecular genetics diagnostic methods are being introduced and include fluorescence in situ 
hybridization (FISH) and chromogenic in situ hybridization (CISH). However, they also have several limitations 
which consist of the inability to estimate the tumor process in vivo and inaccessibility to perform the research in 
most histopathology laboratories. Some of uncertain cases are associated with heterogeneity of the HER2 expression 
that is a serious diagnostic problem for the accurate determination of the receptor status of the tumor.
In this regard, it is still necessary to search for new informative diagnostic methods for detection of malignant 
tumors with overexpression of Her-2/neu. In recent years, the radioisotope techniques are developing for detection 
of specific tumor targets [7]. One of the most studied components for the formation of specific relations with the 
isotopes are “targeting” non-immunoglobulin molecules DARPins (designed ankyrin repeat proteins), which belong 
to a novel class of binding molecules with the potential to overcome the limitations of monoclonal antibodies, hence 
allowing novel therapeutic approaches. The main advantages of such protein structures are a small size (14–20 kDa), 
a stable structure, high specificity to bind with a target, high stability of conjunction, low immunogenicity as well as 
a much lower cost of production [8, 9].
Technetium-99m (99mTc) is the most widely used radionuclide for radiopharmaceuticals, which is characterized 
by availability, short half-life (T1/2 = 6.05 h), low cost and operation of 99mTc generators, as well as simple 
technology of obtaining eluate from the generator.
The chelating agent is an important component in a radiochemical synthesis for binding with 99mTc, as well as 
for the development of a technique for chemical modification of recombinant address molecules with the retaining 
their ability to bind with specific receptors of tumor cells [10–12].
MATERIAL AND METHODS
DARPinG3 was amplified from plasmid pCG-Hnse-DARPin-d18-G3 using specific primers 5'-cgccgaattctt-
gcaggtttcagccag by our colleagues from the M.M. Shemyakin–Yu.A. Ovchinnikov Institute of Bioorganic Che-
mistry of the Russian Academy of Sciences.
Technetium eluate for research was obtained from technetium generators “99mTc-GT-TOM”. Pertechnetate ions 
from the initial generator eluate have a higher degree of oxidation (VII) and high chemical activity without tendency 
to complex formation. Various reducing agents are used for reducing their oxidation state. In our work, stannous 
chloride (SnCl2 Â 2H2O) was used as the reducing agent.
In this study, we used succinimid-1-yl 6-(bis(pyridin-2-ylmethyl)amino)hexanoate (DPAH-NHS ester) as the 
chelating agent.
PREPARATION OF RADIOPHARMACEUTICAL
7RPL[WXUH D UDGLRSKDUPDFHXWLFDO  ȝO RI PJPO RI'3$H–DARPinG3 solution (in phosphate buffer), 
60 ȝO VRGLXP FLWUDWH VROXWLRQ DW D FRQFHQWUDWLRQ RI  PJPO – ȝO RI D VROXWLRQ RI 6Q&O2 2H2O at a 
concentration of 7 mg/ml and 1 ml of a 99mTc eluate with activity of 0.5–3.7 GBq were added in a 10 cc (cubic
centimeter) bottle without inserting an air needle. The radiopharmaceutical is ready for use after mixing and 
incubation for 30 min at room temperature.
The radiochemical purity (RCP) and radiochemical yield (RCY) of the produced pharmaceuticals were 
determined by the method of thin layer chromatography (TLC), using plates PTLC silicagel-AF-A-UV (Sorbfil). 
Two systems were used as mobile phases: 1) acetone and 2) C2H5OH : 25% NH4OH : H2O ÷ 2 : 5 : 5. With acetone, 
the free pertechnetate migrates with the solvent front, whereas colloidal 99mTc and 99mTc–DPAH–DARPinG3 
both remain at the application point. With mix (2) as the mobile phase, colloidal 99mTc remains at the application 
point, whereas free pertechnetate and 99mTc–DPAH–DARPinG3 move with the solvent front. The activity 
distribution of 99mTc on radiochromatograms was studied using the GammaScan-01A setup.
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CELL LINES AND INCUBATION CONDITION
The human breast adenocarcinoma HER2-overexpressing cell line BT-474 (Russian Cell Culture Collection) was 
chosen to detect specific binding. As a control, HER2-negative human breast adenocarcinoma MCF-7 (Russian Cell 
Culture Collection) was used.
CELL LINES RADIOLABELING
The human breast adenocarcinoma BT-474 and MCF-7 cell lines were seeded in chamber-slides at the density of 
35,000 cells/ml in trypsin–EDTA (PanEco) medium and grown overnight at 37°C. After that both cell lines were 
washed with phosphate buffered saline (PBS) and distributed into test tubes to 1 mL (5 millions cells in each). After 
adding 100 μl (70 MBq) studied complexes of 99mTc–DPAH–DARPinG3 and 99mTc–DARPinG3, tubes were 
incubated for 40 min at +4°C. Washing was performed three times with buffer PBS and 5% Bovine Serum Albumin 
(BSA).
Activity measurement was performed with a radiometer for in vitro studies (“Amplituda” 2008 YG). Visual 
scintigraphic and quantitative evaluation was performed using a SPECT (“E.CAM180”), processing the data was 
carried using specialized software package (Esoft 5.5 Siemens, Germany).
Statistical evaluation of the results was performed using the software package of “STATISTICA” for Windows.
RESULTS AND DISCUSSION
The results of binding DPAH–DARPinG3 with technetium-99m depending on the amount of relucting agent are 
showed in Table 1. As can be seen from the presented data, the largest radiochemical yield with a low impurity 
content of unreduced and hydrolyzed technetium-PZDVREVHUYHG LQ FDVHRI DGGLQJ ȝO VROXWLRQRI VWDQQXP
FKORULGHWRȝOVROXWLRQRI'3$+–'$53LQ*DQGȝOVRGLXPFLWUDWHVROXWLRQLWZas more than 91.0%.
The radiochemical yield was dropping as a large amount of stannum chloride was added due to the increase of 
formed hydrolyzed technetium-99m colloid. Thus further in vitro studies were performed with a compound having 
the following compositioQ  ȝO VROXWLRQ RI'3$+–DARPinG3 in a concentration of 0.5 mg/ml (in phosphate 
EXIIHU  ȝO VROXWLRQ RI VRGLXP FLWUDWH LQ D FRQFHQWUDWLRQ RI PJPO  ȝO VROXWLRQ RI 6Q&O2 Â 2H2O with a 
concentration of 7 mg/ml and 99mTc with activity of 0.5–3.7 GBq.
The main mechanism of action of the specific compound based on recombinant target molecules DARPinG3 
consists in their interaction with the receptors on the surface of tumor cells, which makes it possible to detect the 
malignancies with overexpression of the Her-2/neu with high sensitivity and specificity.
The human adenocarcinoma cell line BT-474 with overexpression of Her-2/neu was selected to evaluate the 
specificity of the radiopharmaceutical`s accumulation in the study. The evidence of selective interaction with the 
radiopharmaceutical is a high accumulation on the surface of the group of cells overexpressing Her-2/neu.
Much higher intensity of the accumulation of the studied radiopharmaceutical was detected in the cells’ culture 
with overexpression of the Her-2/neu during a visual scintigraphic evaluation.
In direct radiometry, a higher accumulation of the radiopharmaceutical was revealed also in the human BT-474
mammary adenocarcinoma cell line with overexpression of the Her-2/neu (Table 1).
TABLE 1. Accumulation of radiopharmaceutical “99mTc–DPAH–DARPinG3” ɜFHOOOLQHV%7-ɢ0&)-7
No. experiment
Cell bindings (M ± SD)
p
MCF-7, Mbc BT-474, Mbc
1 0.098 + 0.014 0.306 + 0.038 0.043
2 0.072 + 0.021 0.41 + 0.025 0.038
3 0.087 + 0.019 0.29 + 0.042 0.019
4 0.069 + 0.022 0.31 + 0.039 0.025
5 0.091 + 0.015 0.402 + 0.051 0.003
M—mean value, SD—standard deviation, p—the level of significance of the differences.
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CONCLUSION
A new specific compound based on recombinant target molecules “99mTc–DPAH–DARPinG3” was studied, a 
procedure for its preparation was described, and its specificity and affinity for the Her’s-2/neu receptor were 
characterized. High specificity and stability of this compound make it a promising agent for the diagnosis of 
oncological diseases with overexpression of the Her-2/neu.
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